drugset / Trial / NCT07816250
A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this Phase 2b study is to evaluate the efficacy and therapeutic window of chronically dosed VH4011499 paired with an integrase strand transfer inhibitor (INSTI). This study will explore 4 different regimens of VH4011499 when paired with cabotegravir (CAB) as an initial two-drug regimen.
Timeline
- Start
- 2026-10-19
- Primary completion
- 2032-06-10
- Completion
- 2032-06-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAB | Unknown | — | — |
| Subject | DEZECAPAVIR | Small molecule | — | — |
| Comparator | Dolutegravir | Other / unclassified | 50 mg | Oral |
| Comparator | Lamivudine | Other / unclassified | 300 mg | Oral |